MedTrace Logo

Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer

NCT07714447 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2026-07-21

No results posted yet for this study

Summary

This study investigated the efficacy and safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer.

Conditions

  • CRC (Colorectal Cancer)
  • BRAF

Interventions

DRUG

Arm1

Tunlametinib + Cetuximab β Injection

DRUG

Arm 2

Tunlametinib + Cetuximab β+Tislelizumab

DRUG

Arm 3

Tunlametinib + BRAF inhibitor + Tislelizumab

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-30
Primary Completion
2029-02-01
Completion
2029-02-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07714447 on ClinicalTrials.gov